Table 2.
Phenotypic antimicrobial resistance pattern of the 14 A. baumannii isolates
| ID | AMC | AMP | CFZ | CAZ | CRO | CHL | CIP | GEN | NAL | SXT |
|---|---|---|---|---|---|---|---|---|---|---|
| 116 | I | R | R | R | R | R | R | R | I | R |
| 123C | R | R | R | R | R | R | S | S | I | R |
| 309C | R | R | R | R | R | R | S | R | S | R |
| 043 | R | R | R | R | R | R | R | R | R | R |
| 432B | R | R | R | I | R | R | R | R | R | R |
| 049 | R | R | R | R | R | S | S | S | R | S |
| 033 | I | R | R | S | R | R | S | S | S | S |
| 363 | R | R | R | R | R | R | R | R | R | R |
| 423 | I | R | R | R | R | R | R | R | R | R |
| 518B | S | S | R | R | R | I | I | R | S | R |
| 558 | R | R | R | R | R | R | R | R | R | R |
| 028 | R | R | R | R | R | R | R | R | R | R |
| 164C | I | R | R | S | R | S | S | S | S | S |
| 186B | S | S | S | R | S | S | S | S | R | S |
| R (%) | 57.1 | 85.7 | 92.9 | 78.6 | 92.9 | 71.43 | 50 | 64.3 | 57.1 | 71.4 |
| S (%) | 14.3 | 14.3 | 7.1 | 14.3 | 7.1 | 21.43 | 42.9 | 35.7 | 28.6 | 28.6 |
| I (%) | 28.6 | 0.0 | 0.0 | 7.1 | 0.0 | 7.14 | 7.1 | 0.0 | 14.3 | 0.0 |
AMC, amoxicillin/clavulanate; AMP, ampicillin; CFZ, cefazolin; CAZ, ceftazidime; CRO, ceftriaxone; CHL, chloramphenicol; CIP, ciprofloxacin; GEN, gentamicin; NAL, nalidixic acid; SXT, trimethoprim/sulfamethoxazole; R, resistant; S, susceptible; I, intermediate.